Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–85.

CAS  PubMed  Google Scholar 

Tan HL, Lee M, Vellayappan BA, Neo WT, Yong WP. The role of liver-directed therapy in metastatic colorectal cancer. Curr Colorectal Cancer Rep. 2018;14(5):129–37.

PubMed  PubMed Central  Google Scholar 

Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: metastases to a single organ. World J Gastroenterol. 2015;21(41):11767–76.

PubMed  PubMed Central  Google Scholar 

Li J, Wei X, Liu Y, Cui B. Prognostic significance of distant metastasis location in patients with metastatic colorectal cancers. Int J Clin Exp Med. 2016;9(11):21681–9.

Google Scholar 

Gabriela Chiorean E, Nandakumar G, Fadelu T, Temin S, Alarcon-Rozas AE, Bejarano S, et al. Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline. J Global Oncol. 2020;6:414–38.

Google Scholar 

Swaid F, Tsung A. Current management of liver metastasis from colorectal cancer. Curr Colorectal Cancer Rep. 2018;14(1):12–21.

Google Scholar 

Abedi P, Bayat A, Ghasemzadeh S, Raad M, Pashaiefar H, Ahmadvand M Upregulation of miR-410 is linked with unfavorable prognosis in patients with colorectal cancer. British journal of biomedical science. 2020

Bi F, Wang Q, Dong Q, Wang Y, Zhang L, Zhang J. Circulating tumor DNA in colorectal cancer: opportunities and challenges. Am J Transl Res. 2020;12(3):1044–55.

CAS  PubMed  PubMed Central  Google Scholar 

Chee B, Ibrahim F, Esquivel M, Van Seventer EE, Jarnagin JX, Zhang L, Ju JH, Price KS, Raymond VM, Corvera CU, Hirose K, Nakakura EK, Van Loon K, Corcoran RB, Parikh AR, Atreya CE. Circulating tumor derived cell-free DNA (ctDNA) to predict recurrence of metastatic colorectral cancer (mCRC) following curative intent surgery or radiation. J Clin Oncol. 2021;39(15):3562–5.

Google Scholar 

Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci transl Med. 2020;12(524).

Silva-Fisher JM, Dang HX, White NM, Strand MS, Krasnick BA, Rozycki EB et al. Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression. Nature Communications. 2020;11(1).

Shang P, Gao R, Zhu Y, Zhang X, Wang Y, Guo M, et al. VEGFR2-targeted antibody fused with IFNαmut regulates the tumor microenvironment of colorectal cancer and exhibits potent anti-tumor and anti-metastasis activity. Acta Pharm Sin B. 2021;11(2):420–33.

CAS  PubMed  Google Scholar 

Taïeb J, André T, El Hajbi F, Barbier E, Toullec C, Kim S, et al. Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: the SAMCO-PRODIGE 54 randomised phase II trial. Dig Liver Dis. 2021;53(3):318–23.

PubMed  Google Scholar 

Deschamps F, Ronot M, Gelli M, Durand-Labrunie J, Tazdait M, Hollebecque A, et al. Interventional radiology for colorectal liver metastases. Curr Colorectal Cancer Rep. 2020;16(2):29–37. Review of current IR treatments for mCRC.

Google Scholar 

Van Tilborg AAJM, Meijerink MR, Sietses C, Van Waesberghe JHTM, Mackintosh MO, Meijer S, et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: A potentially curative intervention. Br J Radiol. 2011;84(1002):556–65.

PubMed  PubMed Central  Google Scholar 

Song P, Sheng L, Sun Y, An Y, Guo Y, Zhang Y. The clinical utility and outcomes of microwave ablation for colorectal cancer liver metastases. Oncotarget. 2017;8(31):51792–9.

PubMed  PubMed Central  Google Scholar 

James T, Hill J, Fahrbach T, Collins Z. Differences in radiation activity between glass and resin 90y microspheres in treating unresectable hepatic cancer. Health Phys. 2017;112(3):300–4.

CAS  PubMed  Google Scholar 

Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiol. 2011;259(3):641–57.

Google Scholar 

Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol. 2011;21(4):294–302.

PubMed  PubMed Central  Google Scholar 

Molvar C, Lewandowski RJ. Intra-arterial therapies for liver masses Data Distilled. Radiol Clin North Am. 2015;53(5):973–84.

PubMed  Google Scholar 

Sacco R, Mismas V, Marceglia S, Romano A, Giacomelli L, Bertini M, et al. Transarterial radioembolization for hepatocellular carcinoma: an update and perspectives. World J Gastroenterol. 2015;21(21):6518–25.

PubMed  PubMed Central  Google Scholar 

Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109–22.

CAS  PubMed  Google Scholar 

Ibrahim SM, Lewandowski RJ, Sato KT, Gates VL, Kulik L, Mulcahy MF, et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol. 2008;14(11):1664–9.

PubMed  PubMed Central  Google Scholar 

Grady ED. Internal radiation therapy of hepatic cancer. Dis Colon Rectum. 1979;22(6):371–5.

CAS  PubMed  Google Scholar 

Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, et al. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol. 2004;15(4):335–45. Trial demonstrating glass microspheres safety in unresectable HCC patients with portal vein thrombosis.

PubMed  Google Scholar 

Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterol. 2016;151(6):1155-63.e2.

Google Scholar 

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36.

CAS  PubMed  Google Scholar 

Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21.

CAS  PubMed  Google Scholar 

Ricke J, Sangro B, Amthauer H, Bargellini I, Bartenstein P, De Toni E, et al. The impact of combining selective internal radiation therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the soramic trial palliative cohort. J Hepatol. 2018;68:S102.

Google Scholar 

Van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723–31.

PubMed  Google Scholar 

Khatib J, Kainthla R. Optimal use of FOLFOXIRI plus bevacizumab as first-line systemic treatment in metastatic colorectal cancer. Curr Colorectal Cancer Rep. 2020;16(4):89–95.

Google Scholar 

Core JM, Frey GT, Sharma A, Bussone ST, Legout JD, McKinney JM, et al. Increasing yttrium-90 dose conformality using proximal radioembolization enabled by distal angiosomal truncation for the treatment of hepatic malignancy. J Vasc Interv Radiol. 2020;31(6):934–42. Use of voxel-based dosimetry in Y90 treatment.

PubMed  Google Scholar 

Morán V, Prieto E, Sancho L, Rodríguez-Fraile M, Soria L, Zubiria A et al. Impact of the dosimetry approach on the resulting 90Y radioembolization planned absorbed doses based on 99mTc-MAA SPECT-CT: is there agreement between dosimetry methods? EJNMMI Physics. 2020;7(1)

Skanjeti A, Magand N, Defez D, Tordo J, Rode A, Manichon AF et al. Selective internal radiation therapy of hepatic tumors: morphologic and functional imaging for voxel-based computer-aided dosimetry. Biomed Pharm. 2020;132.

Ahmadzadehfar H, Sabet A, Biermann K, Muckle M, Brockmann H, Kuhl C, et al. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med. 2010;51(8):1206–12.

PubMed  Google Scholar 

Abbott E, Young RS, Hale C, Mitchell K, Falzone N, Vallis KA et al. Stereotactic inverse dose planning after yttrium-90 selective internal radiation therapy in hepatocellular cancer. Adv Rad Oncol. 2021;6(2).

Mok GSP, Dewaraja YK. Recent advances in voxel-based targeted radionuclide therapy dosimetry. Quant Imaging Med Surg. 2021;11(2):483–9.

PubMed  PubMed Central  Google Scholar 

Kafrouni M, Allimant C, Fourcade M, Vauclin S, Delicque J, Ilonca AD, et al. Retrospective voxel-based dosimetry for assessing the ability of the body-surface-area model to predict delivered dose and radioembolization outcome. J Nucl Med. 2018;59(8):1289–95.

CAS  PubMed  Google Scholar 

Haverkamp BT, Pedersen WR, Hunt S, Walter C, Hill JD, Collins ZC. Tumor response time to progression and progression-free survival in glass versus resin radioembolization of hepatocellular cancer. J Vasc Int Radiol. 2017;28(2):e22.

Google Scholar 

Ibrahim SM, Nikolaidis P, Miller FH, Lewandowski RJ, Ryu RK, Sato KT, et al. Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging. 2009;34(5):566–81.

PubMed  Google Scholar 

Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J. 2010;16(2):163–75.

CAS  PubMed  Google Scholar 

DeBacker SJJ, Vavricek J, Iqbal S, Hunt SL et al. Retrospective review of survival outcomes in glass and resin Y-90 microsphere treatment of hepatic malignancies. J Int Radiol Nucl Med. 2018:1–9.

Chiesa C, Mira M, Maccauro M, Romito R, Spreafico C, Sposito C, et al. A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with90Y glass microspheres. Q J Nucl Med Mol Imaging. 2012;56(6):503–8.

CAS  PubMed  Google Scholar 

Kunam V, Shrikanthan S, Srinivas S. Radiation dosimetry of glass versus resin Y-90 microsphere radioembolization in patients with colorectal liver metastases. J Nucl Med. 2012;53(supplement 1):1203.

Google Scholar 

Vente MAD, Wondergem M, van der Tweel I, van den Bosch MAAJ, Zonnenberg BA, Lam MGEH, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol. 2009;19(4):951–9.

CAS  PubMed  Google Scholar 

Biederman DM, Titano JJ, Bishay VL, Durrani RJ, Dayan E, Tabori N, et al. Radiation segmentectomy versus Tace combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study. Radiol. 2017;283(3):895–905.

Google Scholar 

PMA approval for TheraSphere™, 21 CFR 814.39(a)(7) (2021).

Medical S. A Prospective, multicenter, open-label single arm study evaluating the safety & efficacy of selective internal radiation therapy using SIR-spheres® Y-90 resin microspheres on DoR & ORR in unresectable hepatocellular carcinoma patients clinicaltrials.gov2021 [updated March 23, 2021.

Rizzo S, Botta F, Raimondi S, Origgi D, Fanciullo C, Morganti AG, et al. Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp. 2018;2(1):36.

PubMed  PubMed Central  Google Scholar 

Creasy JM, Cunanan KM, Chakraborty J, McAuliffe JC, Chou J, Gonen M, et al. Differences in liver parenchyma are measurable with CT radiomics at initial colon resection in patients that develop hepatic metastases from stage II/III colon cancer. Ann Surg Oncol. 2021;28(4):1982–9.

PubMed  Google Scholar 

Wei L, Cui C, Xu J, Kaza R, El Naqa I, Dewaraja YK. Tumor response prediction in 90Y radioembolization with PET-based radiomics features and absorbed dose metrics. EJNMMI Physics. 2020;7(1).

Eisenhauer EA, Verweij J. New response evaluation criteria in solid tumors: RECIST guideline version 1.1. Eur J Cancer. 2009;7(2–3):5.

Google Scholar 

Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, et al. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Gut. 2020;69(3):531–9. Evaluated the use of radiomics to predict outcomes in patients with mCRC.

CAS  PubMed  Google Scholar 

Shur J, Orton M, Connor A, Fischer S, Moulton CA, Gallinger S, et al. A clinical-radiomic model for improved prognostication of surgical candidates with colorectal liver metastases. J Surg Oncol. 2020;121(2):357–64. Association between clinical features, radiomic features and a combined CRM based on medical imaging.

Google Scholar 

Saini A, Wallace A, Alzubaidi S, Knuttinen MG, Naidu S, Sheth R et al. History and evolution of Yttrium-90 radioembolization for hepatocellular carcinoma. J Clin Med. 2019;8(1).